uprosertib   Click here for help

GtoPdb Ligand ID: 7902

Synonyms: GSK-2141795 | GSK2141795
Compound class: Synthetic organic
Comment: Uprosertib (GSK-2141795) is an inhibitor of the AKT family of protein kinases [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 86.08
Molecular weight 428.06
XLogP 3.23
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NCC(NC(=O)c1oc(c(c1)c1c(Cl)cnn1C)Cl)Cc1ccc(c(c1)F)F
Isomeric SMILES NC[C@@H](NC(=O)c1oc(c(c1)c1c(Cl)cnn1C)Cl)Cc1ccc(c(c1)F)F
InChI InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Uprosertib has progressed to Phase 2 clinical evaluation. In most studies it was administered in combination with other antineoplastics for various oncological indications, such as melanoma, refractory multiple myeloma, acute myeloid leukemia, cervical cancer, endometrial carcinoma and metastatic triple-negative breast cancer. Click here to link to ClinicalTrials.gov's complete list of uprosertib trials.